All Stories

  1. Complement C4, C4A and C4a – What they do and how they differ
  2. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies
  3. Sample processing time but not storage time affects complement activation markers C4a, C4d, C3a, iC3b, Bb, C5a, and sC5b-9 levels in EDTA-plasma of individuals at clinical high-risk for psychosis
  4. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms
  5. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study
  6. Prognostic models predicting transition to psychotic disorder using blood-based biomarkers: a systematic review and critical appraisal
  7. Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis
  8. Associations between plasma inflammatory markers and psychotic disorder, depressive disorder and generalised anxiety disorder in early adulthood: A nested case-control study
  9. Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial
  10. Functional impairment of cortical AMPA receptors in schizophrenia
  11. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
  12. Transdiagnostic inflammatory subgroups among psychiatric disorders and their relevance to role functioning: a nested case-control study of the ALSPAC cohort
  13. Machine learning based prediction and the influence of complement – Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial
  14. The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial
  15. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis
  16. Omega‐3 fatty acid in ultra‐high‐risk psychosis: A systematic review based on functional outcome
  17. Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence
  18. Adolescent-onset and adult-onset schizophrenia: reduced ribosomal protein expression via mTOR signalling in patient-derived olfactory cells
  19. Peripheral complement proteins in schizophrenia: A systematic review and meta-analysis of serological studies
  20. Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment
  21. ApoE elevation is associated with the persistence of psychotic experiences from age 12 to age 18: Evidence from the ALSPAC birth cohort
  22. Integrated Lipidomics and Proteomics Point to Early Blood-Based Changes in Childhood Preceding Later Development of Psychotic Experiences: Evidence From the Avon Longitudinal Study of Parents and Children
  23. Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress
  24. S90. Social Defeat Stress: A Plasma Proteomic Study to Identify Stress Susceptible-Associated and Resilience-Associated Biomarkers
  25. F161. Proteomic Analysis of Blood Based Samples From the OPTiMiSE (OPtimization of Treatment and Management of Schizophrenia in Europe) Study Point Towards Complement Pathway Protein Changes
  26. The Effects of Prenatal Iron Deficiency and Risperidone Treatment on the Rat Frontal Cortex:  A Proteomic Analysis
  27. Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case–Control Study of the ALSPAC Longitudinal Birth Cohort
  28. Human brain proteome in health and disease
  29. Blood biomarker discovery in drug-free schizophrenia: the contribution of proteomics and multiplex immunoassays
  30. Proteomic analysis of the postsynaptic density implicates synaptic function and energy pathways in bipolar disorder
  31. Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
  32. Abstracts from the 5th International Conference for Healthcare and Medical Students (ICHAMS)
  33. Dataset of mouse hippocampus profiled by LC–MS/MS for label-free quantitation
  34. Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus
  35. Reduced protein synthesis in schizophrenia patient-derived olfactory cells
  36. Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: Potential roles in GABAergic interneuron pathology
  37. Maternal Immune Activation Induces Changes in Myelin and Metabolic Proteins, Some of Which Can Be Prevented with Risperidone in Adolescence
  38. Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia
  39. Adolescent Risperidone treatment alters protein expression associated with protein trafficking and cellular metabolism in the adult rat prefrontal cortex
  40. Poster #T144 INTEGRATED GENOMIC AND PROTEOMIC EVIDENCE FOR THE POSTSYNAPTIC DENSITY IN SCHIZOPHRENIA
  41. Poster #T75 PRENATAL EXPOSURE TO MATERNAL IMMUNE STIMULATION LEADS TO CHANGES IN MYELIN PROTEINS IN THE ADULT RAT PREFRONTAL CORTEX WHICH CAN BE PREVENTED BY RISPERIDONE IN ADOLESENCE
  42. SIGNIFICANT DOWN-REGULATION OF EIF2 AND ASSOCIATED RIBOSOMAL PROTEINS IN ONS CELL MODEL OF SCHIZOPHRENIA
  43. Insights from Proteomic Studies on Schizophrenia Preclinical Models: What Can We Learn for Drug Discovery?
  44. Proteomic Investigation of the Hippocampus in Prenatally Stressed Mice Implicates Changes in Membrane Trafficking, Cytoskeletal, and Metabolic Function
  45. Omega-3 fatty acid deficiency disrupts endocytosis, neuritogenesis, and mitochondrial protein pathways in the mouse hippocampus
  46. Proteomic analysis of human hippocampus shows differential protein expression in the different hippocampal subfields
  47. CLATHRIN-MEDIATED-ENDOCYTOSIS AND CLATHRIN-DEPENDENT MEMBRANE AND PROTEIN TRAFFICKING; CORE PATHOPHYSIOLOGICAL PROCESSES IN SCHIZOPHRENIA AND BIPOLAR DISORDER?
  48. Poster #135 MYELIN PATHOLOGYAND ITS RELATIONSHIP TO IRON HOMEOSTASISIN SCHIZOPHRENIA
  49. Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder?
  50. Common Proteomic Changes in the Hippocampus in Schizophrenia and Bipolar Disorder and Particular Evidence for Involvement of Cornu Ammonis Regions 2 and 3
  51. The 2nd Schizophrenia International Research Society Conference, 10–14 April 2010, Florence, Italy: Summaries of oral sessions
  52. PROTEOMIC ANALYSIS OF HIPPOCAMPAL SUB-REGIONS IN SCHIZOPHRENIA AND BIPOLAR DISORDER REVEALS MOST PROMINENT CHANGES IN CA2/3 AND IMPLICATES ABNORMALITIES IN CLATHRIN MEDIATED ENDOCYTOSIS
  53. PROTEOMIC ANALYSIS OF THE BASIC SUB-PROTEOME (PH 6-11) IN THE HIPPOCAMPUS IN SCHIZOPHRENIA AND BIPOLAR AFFECTIVE DISORDER
  54. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease
  55. Hepatocyte Growth Factor/c-MET Axis-mediated Tropism of Cord Blood-derived Unrestricted Somatic Stem Cells for Neuronal Injury
  56. A proteomic investigation of similarities between conventional and herbal antidepressant treatments
  57. PROTEOMIC AND WESTERN BLOT ANALYSIS OF HIPPOCAMPAL SUBREGIONS IN SCHIZOPHRENIA AND BIPOLAR DISORDER
  58. Proteomics Providing Insights into Major Psychiatric Disorders
  59. 2-D DIGE as a quantitative tool for investigating the HUPO Brain Proteome Project mouse series
  60. Caffeine-mediated enhancement of glucocorticoid receptor activity in human osteoblastic cells
  61. Statins potentiate caspase-3 activity in immortalized murine neurons
  62. Host-Dependent Tumorigenesis of Embryonic Stem Cell Transplantation in Experimental Stroke
  63. Chronic glucocorticoid receptor activation impairs CREB transcriptional activity in clonal neurons
  64. Monitoring of implanted stem cell migration in vivo : A highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat
  65. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications.